XML 20 R13.htm IDEA: XBRL DOCUMENT
v3.19.3

Net Loss per Share | 9 Months Ended
--- | ---
Sep. 30, 2019
Net Loss per Share |
Net Loss per Share | 6. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Included in net loss is the Series A preferred dividend from preferred shares issuance of $63,000 and $185,000 for the three and nine months ended September 30, 2019 and $61,000 and $181,000 for the three and nine months ended September 30, 2018, respectively. Net loss for the three and nine months ended September 30, 2019 also includes the Series B deemed dividend of $71,000 and $585,000. The deemed dividend relates to the discount provided to preferred stockholders upon conversion of their preferred stock to common shares and is subtracted from net loss (see Note 8). Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potentially dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. The number of options and warrants for the purchase of Common Stock that were excluded from the computations of net loss per common share for the three and nine months ended September 30, 2019 were 803,577 and 18,915,851, respectively, and for the three and nine months and ended September 30, 2018 were 347,765 and 915,852, respectively. The following tables set forth the computation of diluted net loss per weighted average number of shares outstanding attributable to Synthetic Biologics, Inc. and Subsidiaries for the three and nine months ended September 30, 2019 and 2018 (in thousands except share and per share amounts):
|  | Three months ended September 30, 2019 |  | Nine months ended September 30, 2019
|  | Net loss |  | Shares |  | Per Share |  | Net Loss |  | Shares |  | Per Share
|  | (Numerator) |  | (Denominator) |  | Amount |  | (Numerator) |  | (Denominator) |  | Amount
Net loss - Basic |  | $ | (5,253) |  | 16,805,257 |  | $ | (0.31) |  | $ | (12,934) |  | 16,313,326 |  | $ | (0.79)
Dilutive shares related to warrants |  |  | — |  | — |  |  | — |  |  | — |  | — |  |  | —
Net loss - Dilutive |  | $ | (5,253) |  | 16,805,257 |  | $ | (0.31) |  | $ | (12,934) |  | 16,313,326 |  | $ | (0.79)
|  | Three months ended September 30, 2018 |  | Nine months ended September 30, 2018
|  | Net loss |  | Shares |  | Per Share |  | Net Loss |  | Shares |  | Per Share
|  | (Numerator) |  | (Denominator) |  | Amount |  | (Numerator) |  | (Denominator) |  | Amount
Net loss - Basic |  | $ | (3,741) |  | 4,028,304 |  | $ | (0.93) |  | $ | (10,375) |  | 3,802,812 |  | $ | (2.73)
Dilutive shares related to warrants |  |  | — |  | — |  |  | — |  |  | — |  | — |  |  | —
Net loss - Dilutive |  | $ | (3,741) |  | 4,028,304 |  | $ | (0.93) |  | $ | (10,375) |  | 3,802,812 |  | $ | (2.73)

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration